Personalized treatment selection for metastatic breast cancer
Phase of Trial: Phase II
Latest Information Update: 22 Jul 2015
At a glance
- Drugs Dasatinib (Primary) ; Selumetinib (Primary)
- Indications Advanced breast cancer
- Focus Pharmacogenomic; Therapeutic Use
- 17 Jul 2015 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
- 30 May 2014 Status changed from active, no longer recruiting to completed; according to ClinicalTrials.gov record.
- 13 Nov 2012 Planned number of patients changed from 532 to 769 as reported by ClinicalTrials.gov.